Emily Pasman
Overview
Explore the profile of Emily Pasman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Constantin J, McCabe S, Pasman E, Wilens T, Chua K
Health Aff (Millwood)
. 2025 Mar;
44(3):361-369.
PMID: 40030102
Policy makers have temporarily extended COVID-19 pandemic-related flexibilities allowing controlled substance prescribing via telehealth without in-person visits. To inform debates regarding whether these flexibilities should be permanent, we used commercial...
2.
Schepis T, Veliz P, McCabe V, Werner K, Pasman E, Wilens T, et al.
Exp Clin Psychopharmacol
. 2025 Feb;
PMID: 40014513
Psychostimulant misuse and use disorders are major drivers of morbidity and fatal overdose in the United States, but little is known about how differences in psychostimulant use patterns relate to...
3.
Attention-Deficit/Hyperactivity Disorder Symptoms and Later E-Cigarette and Tobacco Use in US Youths
McCabe S, Pasman E, Wilens T, Boyd C, Veliz P, McCabe V, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2458834.
PMID: 39932711
Importance: Information about longitudinal associations of attention-deficit/hyperactivity disorder (ADHD) diagnosis, symptom severity, pharmacotherapy, and incident nicotine and tobacco use, including e-cigarettes, among US youths is limited. Objective: To evaluate whether...
4.
Pasman E, Evans-Polce R, Schepis T, Engstrom C, McCabe V, Drazdowski T, et al.
J Addict Med
. 2025 Jan;
PMID: 39792600
Objectives: Most US treatment and recovery services are abstinence-based. However, many people in recovery from an alcohol or other drug (AOD) use problem do not abstain completely. This study estimated...
5.
Carl A, Pasman E, Broman M, Lister J, Agius E, Resko S
Drug Alcohol Depend Rep
. 2024 Oct;
9:100201.
PMID: 39473545
[This corrects the article DOI: 10.1016/j.dadr.2023.100138.].
6.
Cioffi C, Flinn R, Pasman E, Gannon K, Gold D, McCabe S, et al.
Int J Drug Policy
. 2024 Sep;
133:104599.
PMID: 39341070
There has been growing attention toward including people with lived and living experience (PWLLE) with substance use, substance use disorders, and recovery in public-facing activities. The goals of including PWLLE...
7.
Pasman E, Blair L, Solberg M, McCabe S, Schepis T, Resko S
Drug Alcohol Depend Rep
. 2024 Sep;
12:100279.
PMID: 39286537
Background: Substance use and substance use disorders (SUD) are prevalent among college students. Information about the gap between substance use treatment need versus treatment receipt can guide efforts to increase...
8.
McCabe S, Pasman E, Wilens T, Schepis T, McCabe V, Ford J, et al.
JAMA
. 2024 Jul;
332(7):587-589.
PMID: 39046750
No abstract available.
9.
Solberg M, Pasman E, OShay S, Friedrich F, Agius E, Resko S
Subst Use Misuse
. 2024 May;
59(9):1416-1423.
PMID: 38733118
: Chronic non-cancer pain affects 20% of Americans. This is significantly impacted by the ongoing opioid crisis and reduced opioid dispensing. Public perceptions additionally shape pain management strategies. : This...
10.
Pasman E, Lee G, Singer S, Burson N, Agius E, Resko S
Am J Drug Alcohol Abuse
. 2024 Apr;
50(3):391-400.
PMID: 38640497
Peer recovery specialists (PRSs) are substance use service providers with lived experience in recovery. Although a large body of research demonstrates the efficacy of medications for opioid use disorder (MOUD),...